Infantile Spasms Clinical Trial
Official title:
Evaluation of the Modified Atkins Diet in Children With Infantile Spasms Refractory to Hormonal Therapy: a Randomized Controlled Trial
Verified date | April 2013 |
Source | Lady Hardinge Medical College |
Contact | n/a |
Is FDA regulated | No |
Health authority | India: Ministry of Health |
Study type | Interventional |
Infantile spasms comprise an infantile epileptic encephalopathy characterized by
hypsarrhythmia on EEG, and frequent neurodevelopmental regression. Unfortunately the
treatment of this disorder remains difficult. The first-line options which include hormonal
therapy, i.e., adrenocorticotropic hormone (ACTH) or oral corticosteroids, and vigabatrin
are effective in 60-70% of the patients. Hormonal therapy is considered the best available
treatment. Vigabatrin being expensive and of limited availability is not a feasible option
for most patients in our setting. Also, these are however associated with significant side
effects, and high relapse rates. Newer drugs such as topiramate, zonisamide, and
levetiracetam have also been evaluated; however these drugs are less effective than ACTH.
The ketogenic diet (KD) is a high fat, low carbohydrate diet. It has been used for treatment
of intractable childhood epilepsy. The KD has also been shown to be effective for
intractable infantile spasms; often after ACTH and vigabatrin have failed.
The modified Atkins diet is a non-pharmacologic therapy for intractable childhood epilepsy
that was designed to be a less restrictive alternative to the traditional ketogenic diet.
This diet is started on an outpatient basis without a fast, allows unlimited protein and
fat, and does not restrict calories or fluids. Preliminary data have shown efficacy in
refractory infantile spasms. This diet is also ideal for resource-constraint settings with
paucity of trained dieticians. Hence this study has been planned to evaluate the efficacy
and tolerability of the modified Atkins diet in children with infantile spasms refractory to
hormonal treatment in a randomized controlled trial.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 2013 |
Est. primary completion date | October 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 9 Months to 36 Months |
Eligibility |
Inclusion Criteria: 1. age 9 months to 3 years 2. Presence of epileptic spasms in clusters in child 9 months to < 3years of age, with electroencephalographic evidence of hypsarrhythmia or its variants), persisting, at least one cluster per day, despite treatment with either oral corticosteroids or adrenocorticotrophic hormone (ACTH) and one additional anticonvulsant (valproate/benzodiazepine/vigabatrin/topiramate/zonisamide/ levetiracetam) for at least 4 weeks. Exclusion Criteria: - Children with known or suspected inborn error of metabolism, Patients with clinical suspicion of metabolic disorder as evidenced by 2 or more of the following: - a history of parental consanguinity, - prior affected siblings, - unexplained vomiting, - intermittent worsening of symptoms, - recurrent episodes of lethargy, - altered sensorium, or - ataxia, - hepatosplenomegaly on examination - With or without 2 or more of the following biochemical abnormalities: - High blood ammonia (> 80mmol/L), - High arterial lactate (> 2 mmol/L), - metabolic acidosis (pH < 7.2), - hypoglycaemia (blood sugar < 40 mg/dl), - abnormal urinary aminoacidogram, - presence of reducing sugars or ketones in urine, and - positive results on urine neurometabolic screening tests. In such patients, blood tandem mass spectrometry or urine gas chromatography mass spectroscopy (GCMS) will be obtained to look for inborn error of metabolism. - Children with renal, pulmonary, cardiac or hepatic dysfunction - Severe malnutrition (weight for length and height for age less than 3 SD for mean as per WHO growth charts), - Children from families who lack motivation will also be excluded as it might affect the compliance. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
India | Lady Hardinge Medical College and Associated Kalawati Saran Children's Hospital | New Delhi | Delhi |
Lead Sponsor | Collaborator |
---|---|
Lady Hardinge Medical College |
India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of children who achieved spasm freedom as per parental reports at 4 weeks | 4 weeks | No | |
Secondary | Proportion of children who achieved >50% reduction of clinical spasm, as per parental reports at 4 weeks | 4 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02299115 -
Prednisolone Versus Vigabatrin in the First-line Treatment of Infantile Spasms
|
Phase 3 | |
Completed |
NCT02885389 -
Molecular Genetics in Infantile Spasms
|
N/A | |
Completed |
NCT01006811 -
Use of the Modified Atkins Diet in Infantile Spasms
|
Phase 2/Phase 3 | |
Completed |
NCT01828437 -
Addition of Pyridoxine to Prednisolone in Infantile Spasms
|
Phase 3 | |
Recruiting |
NCT01858285 -
Genetics of Epilepsy and Related Disorders
|
||
Completed |
NCT00552045 -
Epilepsy Phenome/Genome Project
|
||
Completed |
NCT02220114 -
Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy
|
N/A | |
Completed |
NCT02954887 -
Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)
|
Phase 3 | |
Completed |
NCT01723787 -
Genetic Studies in Patients and Families With Infantile Spasms
|
||
Completed |
NCT02092883 -
Evaluation of Neuroinflammation in Children With Infantile Spasms
|
Phase 4 | |
Withdrawn |
NCT01413711 -
An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile Spasms
|
Phase 4 | |
Completed |
NCT00441896 -
A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms
|
Phase 2 | |
Terminated |
NCT00442104 -
Open-label Extension to Protocol 1042-0500
|
Phase 2 | |
Completed |
NCT01575639 -
Prednisolone in Infantile Spasms- High Dose Versus Usual Dose
|
Phase 3 | |
Not yet recruiting |
NCT06315829 -
Artificial Intelligence-based Video Analysis to Detect Infantile Spasms
|
||
Completed |
NCT01073579 -
Sabril Patient Registry
|
N/A | |
Completed |
NCT02953548 -
Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)
|
Phase 3 | |
Completed |
NCT00001325 -
Metabolic Abnormalities in Children With Epilepsy
|
N/A | |
Completed |
NCT00968136 -
Short-term Ketogenic Diet as Compared With Conventional Long-term Trial in Refractory Infantile Spasms: A Randomized, Controlled Study
|
N/A |